Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM StudyRecruiting
NCT06593327NAUpdated Feb 27, 2026
Sponsor: University of Texas Southwestern Medical Center
Type 2 Diabetes · Diabetic Cardiomyopathy · Heart Failure · Cardiometabolic Diseases
United States
A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME)Completed
NCT06723288N/AUpdated Feb 27, 2026
Sponsor: Hoffmann-La Roche
Neovascular Age-related Macular Degeneration · Diabetic Macular Edema
Spain
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerCompleted
NCT05896566Phase 2Updated Feb 24, 2026
Sponsor: ETOP IBCSG Partners Foundation
Breast Cancer
France, Germany, Ireland, Italy, Spain +1 more
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisActive Not Recruiting
NCT04035005Phase 3Updated Feb 23, 2026
Sponsor: Hoffmann-La Roche
Multiple Sclerosis, Primary Progressive
United States, Australia, Belgium, Bulgaria, Canada +18 more
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid TumorsRecruiting
NCT04354064N/AUpdated Feb 20, 2026
Sponsor: Washington University School of Medicine
Healthy Volunteer · Prostate Cancer · Head and Neck Cancer · Esophageal Cancer
United States
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast CancerCompleted
NCT04024462Phase 3Updated Feb 20, 2026
Sponsor: Hoffmann-La Roche
HER2-positive Early Breast Cancer
China
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell TransplantationCompleted
NCT02867384Phase 2Updated Feb 19, 2026
Sponsor: Dana-Farber Cancer Institute
Graft vs. Host Disease
United States
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab TreatmentRecruiting
NCT06675955Phase 3Updated Feb 18, 2026
Sponsor: Hoffmann-La Roche
Multiple Sclerosis
France, Germany, Russia, Ukraine
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple SclerosisCompleted
NCT03593590N/AUpdated Feb 17, 2026
Sponsor: Hoffmann-La Roche
Multiple Sclerosis
Austria, Belgium, Brazil, Bulgaria, Chile +20 more
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerActive Not Recruiting
NCT04665856Phase 3Updated Feb 13, 2026
Sponsor: Hoffmann-La Roche
Small Cell Lung Carcinoma
China
Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-BlockadeActive Not Recruiting
NCT06068985Phase 2Updated Feb 12, 2026
Sponsor: Latin American Cooperative Oncology Group
Breast Cancer · HER2-positive Breast Cancer
Brazil
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast CancerCompleted
NCT05415215Phase 3Updated Feb 10, 2026
Sponsor: Hoffmann-La Roche
Early Breast Cancer · Locally Advanced Breast Cancer · Inflammatory Breast Cancer
Argentina, Bosnia and Herzegovina, Brazil, Bulgaria, Canada +12 more
Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With RadiotherapyActive Not Recruiting
NCT03474094Phase 2Updated Feb 10, 2026
Sponsor: Centre Leon Berard
Sarcoma,Soft Tissue
France, United Kingdom
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)Recruiting
NCT04895436Phase 2Updated Feb 9, 2026
Sponsor: AbbVie
Chronic Lymphocytic Leukemia (CLL)
United States, Australia, Austria, Brazil, Bulgaria +6 more
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular EdemaCompleted
NCT04432831Phase 3Updated Feb 9, 2026
Sponsor: Hoffmann-La Roche
Diabetic Macular Edema
United States, Argentina, Australia, Austria, Brazil +25 more
A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal CancerWithdrawn
NCT07323576Phase 2Updated Feb 9, 2026
Sponsor: Hoffmann-La Roche
Colorectal Cancer
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790MCompleted
NCT03133546Phase 2Updated Feb 6, 2026
Sponsor: ETOP IBCSG Partners Foundation
Non Small Cell Lung Cancer Metastatic
Ireland, Netherlands, Singapore, South Korea, Spain +1 more
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical StudyEnrolling By Invitation
NCT05967351Phase 3Updated Feb 6, 2026
Sponsor: Sarepta Therapeutics, Inc.
Duchenne Muscular Dystrophy
United States, Belgium, Germany, Hong Kong, Italy +4 more
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast CancerActive Not Recruiting
NCT06175390Phase 2Updated Feb 6, 2026
Sponsor: Institut Curie
Triple Negative Breast Cancer
France
NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line TherapyRecruiting
NCT07365930N/AUpdated Feb 5, 2026
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Carcinoma (HCC)
Germany
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompleted
NCT05110846Phase 2Updated Feb 5, 2026
Sponsor: Carmot Therapeutics, Inc.
Obesity · Overweight · Type 2 Diabetes Mellitus
Mexico
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic MelanomaCompleted
NCT05419388Phase 2Updated Feb 4, 2026
Sponsor: Hoffmann-La Roche
Melanoma
Australia, Brazil, Canada, Czechia, Greece +5 more
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell LymphomasNot Yet Recruiting
NCT07387848Phase 2Updated Feb 4, 2026
Sponsor: American University of Beirut Medical Center
Diffuse Large B Cell Lymphoma Refractory
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian CancerTerminated
NCT05756907Phase 1, Phase 2Updated Feb 3, 2026
Sponsor: Sonnet BioTherapeutics
Advanced Solid Tumor · Platinum-resistant Ovarian Cancer
United States, Australia
Screening Study for Participants With Malignant TumorsCompleted
NCT05419375Phase 2Updated Feb 3, 2026
Sponsor: Hoffmann-La Roche
Solid Tumors
United States, Australia, Brazil, Canada, Chile +21 more

Previous page Next page